Axsome Therapeutics (NASDAQ:AXSM) Price Target Raised to $160.00

Axsome Therapeutics (NASDAQ:AXSM) had its price target upped by Robert W. Baird from $132.00 to $160.00 in a report issued on Monday,Benzinga reports. Robert W. Baird currently has an outperform rating on the stock.

Other research analysts also recently issued research reports about the stock. Truist Financial raised their price target on shares of Axsome Therapeutics from $190.00 to $200.00 and gave the stock a “buy” rating in a research note on Wednesday, February 19th. Morgan Stanley increased their target price on shares of Axsome Therapeutics from $125.00 to $190.00 and gave the stock an “overweight” rating in a report on Thursday, February 27th. Deutsche Bank Aktiengesellschaft began coverage on shares of Axsome Therapeutics in a report on Tuesday, February 11th. They set a “buy” rating and a $176.00 target price on the stock. Royal Bank of Canada increased their target price on shares of Axsome Therapeutics from $143.00 to $192.00 and gave the stock an “outperform” rating in a report on Wednesday, February 19th. Finally, HC Wainwright increased their target price on shares of Axsome Therapeutics from $190.00 to $200.00 and gave the stock a “buy” rating in a report on Thursday, February 20th. One analyst has rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $167.36.

Axsome Therapeutics Trading Down 0.4 %

AXSM stock opened at $125.10 on Monday. The company has a market capitalization of $6.10 billion, a PE ratio of -20.88 and a beta of 0.99. Axsome Therapeutics has a 12 month low of $64.11 and a 12 month high of $139.13. The firm’s 50-day moving average is $107.34 and its 200 day moving average is $97.28. The company has a debt-to-equity ratio of 3.22, a current ratio of 2.11 and a quick ratio of 2.04.

Axsome Therapeutics (NASDAQ:AXSM) last posted its quarterly earnings results on Tuesday, February 18th. The company reported ($0.96) EPS for the quarter, topping the consensus estimate of ($0.97) by $0.01. The company had revenue of $118.77 million for the quarter, compared to the consensus estimate of $117.83 million. Axsome Therapeutics had a negative net margin of 74.47% and a negative return on equity of 223.51%. On average, research analysts anticipate that Axsome Therapeutics will post -2.79 EPS for the current year.

Insider Activity

In related news, CFO Nick Pizzie sold 3,000 shares of Axsome Therapeutics stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $131.07, for a total value of $393,210.00. Following the completion of the sale, the chief financial officer now directly owns 42,187 shares in the company, valued at $5,529,450.09. This trade represents a 6.64 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 22.40% of the company’s stock.

Institutional Trading of Axsome Therapeutics

A number of institutional investors have recently bought and sold shares of AXSM. Raiffeisen Bank International AG acquired a new stake in Axsome Therapeutics in the 4th quarter worth approximately $51,000. Assetmark Inc. acquired a new stake in Axsome Therapeutics in the 4th quarter worth approximately $52,000. R Squared Ltd acquired a new stake in Axsome Therapeutics in the 4th quarter worth approximately $64,000. Aquatic Capital Management LLC acquired a new stake in Axsome Therapeutics in the 4th quarter worth approximately $76,000. Finally, GF Fund Management CO. LTD. acquired a new stake in Axsome Therapeutics in the 4th quarter worth approximately $86,000. 81.49% of the stock is currently owned by institutional investors and hedge funds.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.